British Lung Foundation/United Kingdom Primary Immunodeficiency Network Consensus Statement on the Definition, Diagnosis, and Management of Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders
Year: 2017
Type: article
Abstract: A proportion of people living with common variable immunodeficiency disorders develop granulomatous-lymphocytic interstitial lung disease (GLILD). We aimed to develop a consensus statement on the definition, diagnosis, and management of GLILD. All UK specialist centers were contacted and relevant physicians were invited to take part in a 3-round online Delphi process. Responses were graded as Strongly Agree, Tend to Agree, Neither Agree nor Disagree, Tend to Disagree, and Strongly Disagree, scored +1, +0.5, 0, -0.5, and -1, respectively. Agreement was defined as greater than or equal to 80% consensus. Scores are reported as mean ± SD. There was 100% agreement (score, 0.92 ± 0.19) for the following definition: "GLILD is a distinct clinico-radio-pathological ILD occurring in patients with [common variable immunodeficiency disorders], associated with a lymphocytic infiltrate and/or granuloma in the lung, and in whom other conditions have been considered and where possible excluded." There was consensus that the workup of suspected GLILD requires chest computed tomography (CT) (0.98 ± 0.01), lung function tests (eg, gas transfer, 0.94 ± 0.17), bronchoscopy to exclude infection (0.63 ± 0.50), and lung biopsy (0.58 ± 0.40). There was no consensus on whether expectant management following optimization of immunoglobulin therapy was acceptable: 67% agreed, 25% disagreed, score 0.38 ± 0.59; 90% agreed that when treatment was required, first-line treatment should be with corticosteroids alone (score, 0.55 ± 0.51).
Authors: John R. Hurst, Nisha Verma, David Lowe, Helen E. Baxendale, Stephen Jolles, Peter Kelleher, Hilary J. Longhurst, Smita Y. Patel, Elisabetta A. Renzoni, Clare R. Sander, Gerard R. Avery, Judith L. Babar, Matthew S. Buckland, Siobhan Burns, William Egner, Mark M. Gompels, Pavels Gordins, Jamanda A. Haddock, Simon P. Hart, Grant R. Hayman, Richard Herriot, Rachel K. Hoyles, Aarnoud P. Huissoon, Joseph Jacob, Andrew G. Nicholson, Doris M. Rassl, Ravishankar B. Sargur, Sinisa Savic, Suranjith L. Seneviratne, Michael Sheaff, Prashantha M. Vaitla, Gareth I. Walters, Joanna L. Whitehouse, Penny A. Wright, Alison M. Condliffe
Institutions: University College London, The Royal Free Hospital, Royal Papworth Hospital, University Hospital of Wales, Royal Brompton & Harefield NHS Foundation Trust, Harefield Hospital, Imperial College London, Barts Health NHS Trust, NIHR Oxford Biomedical Research Centre, Royal Brompton Hospital, Hull University Teaching Hospitals NHS Trust, University of Cambridge, Cambridge University Hospitals NHS Foundation Trust, Sheffield Teaching Hospitals NHS Foundation Trust, North Bristol NHS Trust, Castle Hill Hospital, Royal Free London NHS Foundation Trust, University of Hull, Hull York Medical School, Epsom and St Helier University Hospitals NHS Trust, Aberdeen Royal Infirmary, Churchill Hospital, University of Oxford, Heartlands Hospital, St James's University Hospital, Nottingham University Hospitals NHS Trust, Heart of England NHS Foundation Trust, University of Sheffield
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $4,000
Funders: Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, CSL Behring, Baxalta, PTC Therapeutics, Cancer Research UK, British Lung Foundation, Imperial College London, Imperial College Healthcare NHS Trust, University College London, Swedish Orphan Biovitrum, Grifols, Medical Research Council, Innovate UK, UCB Pharma
OpenAlex ID: W2603625002
